Investor Alert: Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of Theragenics Corporation

Holzer Holzer & Fistel, LLC is investigating whether the directors of Theragenics Corporation (“Theragenics” or the “Company”) (NYSE: TGX) complied with their fiduciary duties in approving the proposed acquisition of the Company by Juniper Investment Company. Under the proposed terms of the buyout, Theragenics shareholders would receive $2.20 per share for each share of TGX owned. The firm’s investigation seeks to determine, among other things, whether the consideration to be paid to Theragenics shareholders is fair and adequate.

Current holders of Theragenics common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024